Margarita Donica

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

Filippo Montemurro, Suzette Delaloge, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

Filippo Montemurro, Antonio Antón, Rachel Wuerstlein et al. · European Journal of Cancer · 2019 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D.W. Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2020 · 97 citations

Medicine, Oncology, Pharmacology +16

An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)

Jean‐Luc Raoul, RS Finn, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2009 · 68 citations

Medicine, Oncology, Pharmacology +17

Phase <scp>II</scp> study (<scp>KAMELEON</scp>) of single‐agent <scp>T‐DM1</scp> in patients with <scp>HER2</scp>‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

Elisabeth G.E. de Vries, Josef Rüschoff, Martijn P. Lolkema et al. · Cancer Medicine · 2023 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17